Malaria is an infectious disease caused by Plasmodiumspp. parasites. Current important problem of malaria treatment is the rise of parasites resistant to currently available antimalarial drugs. Thus there is an urgent need to develop new drugs that effectively kill drug resistant parasites.
BIOTEC research team, in collaboration with researchers from both local and international universities, has successfully developed new antimalarial drug candidate ‘P218’ that targets malarial enzyme dihydrofolate reductase (DHFR) and effectively kills both sensitive and resistant parasites.
P218 has been selected by Medicines for Malaria Ventures, a not-for-profit organization, for further development, and is currently undergoing a pre-clinical study.